ADIPOQ and metabolic syndrome: Clinically, this presents as hyperinsulinemia, dyslipidemia, hyperglycemia, elevated circulating inflammatory markers, and diminished plasma adiponectin levels, with increased morbidity and mortality due to cardio- and cerebro-vascular diseases or kidney and liver dysfunction and failure (Padmalayam and Suto, 2013; Grundy, 2015; Taskinen and Boren, 2015).